Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | MITF | O75030 | 2/20 | 0.58 |
| ▸ | XBP1 | P17861 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25167513 | 0.91 | RNF4 (0.68) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL9081388 | 0.84 | NPC1 (0.76) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL12233865 | 0.83 | MAPT (0.58) | NPC1RAB9AXBP1SMN1; SMN2HTT | |
| SCHEMBL13167576 | 0.81 | RAB9A (0.65) | NPC1RAB9AXBP1SMN1; SMN2HTT | |
| SCHEMBL4008934 | 0.81 | EPHX2 (0.63) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL8288211 | 0.81 | NPC1 (0.54) | NPC1RAB9AXBP1SMN1; SMN2HTT | |
| SCHEMBL9429422 | 0.81 | MAPT (0.59) | NPC1RAB9AXBP1SMN1; SMN2HTT | |
| SCHEMBL3043118 | 0.81 | NPC1 (0.54) | NPC1RAB9AXBP1SMN1; SMN2HTT | |
| SCHEMBL19240371 | 0.81 | KIF11 (0.59) | NPC1RAB9AXBP1NPSR1SMN1; SMN2 | |
| SCHEMBL6857771 | 0.81 | SMN1; SMN2 (0.59) | NPC1RAB9AXBP1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685392-B | Phenyl-tetrazole oxime derivative and preparation method and application thereof | 东莞市东阳光农药研发有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-08 | — | — | US | disclosed |
| CN-114685392-A | Phenyl-tetrazole oxime derivative and preparation method and application thereof | 东莞市东阳光农药研发有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2021219089-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (CN) | 2021-11-04 | — | — | WO | disclosed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
| US-4661494-A | POWDERY MILDEW | CHEVRON RESEARCH COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| US-4532251-A | N-substituted-N',N'-disubstituted glycinamide fungicides | CHEVRON RESEARCH COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | NPC1 1354/4885RAB9A 2999/4885MITF 4628/4885 |
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, SARS1, ACE | NPC1 839/4885RAB9A 3242/4885MITF 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.